BUDESONIDE

💡

Quick Summary

Budesonide is a synthetic corticosteroid with potent anti-inflammatory and immunosuppressive properties, primarily used in the management of asthma, chronic obstructive pulmonary disease (COPD), allergic rhinitis, and inflammatory bowel disease (IBD). It exerts its effects by binding to cytosolic glucocorticoid receptors, translocating to the nucleus, and modulating the transcription of multiple inflammatory genes. Its clinical utility is heavily defined by its high first-pass metabolism (approximately 90%), which allows for targeted topical delivery to the respiratory tract or gastrointestinal lumen with minimal systemic corticosteroid exposure. The most critical clinical consideration is ensuring the correct formulation is selected for the target organ, as inhaled, intranasal, and delayed-release oral formulations are not interchangeable and possess distinct pharmacokinetic profiles.

🔬

Drug Identity

GENERIC NAMEBudesonide
MEDOBO IDMDBD0075
ATC CODER03BA02
PHARMACOLOGICAL CLASSGlucocorticoid
THERAPEUTIC CLASSAnti-inflammatory Agent
THERAPEUTIC CATEGORYRespiratory
CHEMICAL NAME(11β,16α)-16,17-(butylidenedioxy)-11,21-dihydroxypregna-1,4-diene-3,20-dione
DRUG SOURCESynthetic
FDA APPROVAL1989
MODALITYSmall Molecule
DRUG TYPEstandard
MARKET STATUS● Approved
CORE USE TAGS
AsthmaCOPDCrohn's DiseaseUlcerative ColitisAllergic RhinitisCorticosteroid
BRAND NAMES (GLOBAL)
PulmicortEntocortRhinocortSymbicortUceraseCortimentSpirocortMiflonideNovopulmonTafenBudecortInflamidePulmocortEntocort ECRhinocort AquaSymbicort TurbohalerCiclocortBreztri
SYNONYMS
BudesonidumBudesonidaS-1320Pregna-1,4-diene-3,20-dione, 16,17-(butylidenedioxy)-11,21-dihydroxy-, (11beta,16alpha)-
📌

Indications & Uses

🎯 APPROVED INDICATIONS
  • Asthma — maintenance treatment of asthma as prophylactic therapy in adults and pediatric patients
  • Chronic Obstructive Pulmonary Disease (COPD) — maintenance treatment of airflow obstruction in patients with COPD, including chronic bronchitis and emphysema
  • Allergic Rhinitis — management of symptoms of seasonal and perennial allergic rhinitis
  • Crohn's Disease — induction of remission in patients with mild to moderate active Crohn's disease involving the ileum and/or ascending colon
  • Ulcerative Colitis — induction of remission in patients with mild to moderate active ulcerative colitis (specific delayed-release formulations)
🔬 OFF-LABEL USES
  • Eosinophilic Esophagitis (EoE) — swallowed aerosol or oral viscous suspension to reduce esophageal eosinophilia and dysphagia
  • Microscopic Colitis (lymphocytic and collagenous) — first-line therapy for inducing remission of chronic watery diarrhea
  • Croup (acute laryngotracheobronchitis) — single dose of nebulized budesonide to reduce airway edema in pediatric emergency settings
  • IgG4-related disease — used as a steroid-sparing or induction agent in specific localized manifestations
  • Nasal polyposis — off-label use of intranasal sprays or budesonide added to saline rinses to reduce polyp size
MEDICAL DISCLAIMER — This content is intended for educational purposes and qualified healthcare professionals only. Always refer to current prescribing information, institutional protocols, and official clinical guidelines. Medobo is not responsible for clinical decisions made based on this content.